Rheumatology Medical News about adalimumab

Your Unread Messages

See All

Tracy Hampton, PhD

Conference Flash

Sorafenib Improves Breast Cancer Patients' Progression-Free Survival

Roberta Buell, MBA
HIPAA Breaches Must Be Reported Soon

Dorothy J. Schirf, MD

Technology Advances

Over-the-Counter Nanotech Test for Prostate Cancer Anticipated

Sara Hartley

Technology Advances

A New Strategy for Protecting Ovaries in Young Cancer Patients

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis
Rheumatology International, 11/02/09

Takase K et al. – Infliximab has demonstrated remarkable effects on controlling uveitis in patients with Behcet’s disease (BD). However, there is no way except for discontinuation of infliximab treatment in patients who are intolerant to the agent due to hypersensitivity reactions. Discontinuation of the therapy led to another ocular attacks immediately. Switching to adalimumab induced clinical remission again. The experience suggest adalimumab is a safe and effective option for patients having hypersensitivity to infliximab.

<< Previous
Molecular diagnostics of hereditary fever syndromes

Next >>
Autoinflammatory diseases in childhood